Belle Van Rosmalen
Company: Eli Lilly
Job title: Director, Medical Development, Incretin Outcomes
Seminars:
9:00 am Formulating Innovative & Patient Centred Phase 3 Trials to Improve Results for Translating More Drugs to Clinic 9:00 am
Designing Phase III MASH trials to integrate robust methodologies and evaluating efficacy and safety across diverse patient populations, accelerating the path to regulatory approval to bring therapies to patients faster Incorporating non-invasive testing throughout Phase III trials to reduce patient burden and enhance data collection efficiency, leading to more comprehensive and patient-friendly assessments of treatment…Read more
day: Conf day 2
1:45 pm Roundtable Discussion: Adapting Trial Methodologies to Reflect Real-World MASH Populations to Broaden Treatment Applicability 1:45 pm
Implementing more inclusive trial designs that incorporate diverse patient populations to ensure trial results are generalizable to a broader range of MASH patients to lead to more effective and equitable treatment strategies Utilizing real-world data (RWD) and patient registries to provide valuable insights into disease progression and treatment outcomes in routine clinical practice to complement…Read more
day: Conf day 2